• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex percutaneous coronary intervention.

作者信息

Ortega-Paz Luis, Angiolillo Dominick J

机构信息

Division of Cardiology, University of Florida College of Medicine, ACC Building 5th floor, 655 West 8th Street Jacksonville, FL 32209, USA.

出版信息

Eur Heart J. 2022 Sep 1;43(33):3115-3117. doi: 10.1093/eurheartj/ehac369.

DOI:10.1093/eurheartj/ehac369
PMID:35861271
Abstract
摘要

相似文献

1
Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex percutaneous coronary intervention.接受复杂经皮冠状动脉介入治疗的高出血风险患者的最佳抗血小板治疗
Eur Heart J. 2022 Sep 1;43(33):3115-3117. doi: 10.1093/eurheartj/ehac369.
2
Perceived or Calculated Bleeding Risk and Their Relation With Dual Antiplatelet Therapy Duration in Patients Undergoing Percutaneous Coronary Intervention.经皮冠状动脉介入治疗患者的感知或计算出血风险及其与双联抗血小板治疗持续时间的关系
Circ Cardiovasc Interv. 2019 Jun;12(6):e007949. doi: 10.1161/CIRCINTERVENTIONS.119.007949. Epub 2019 May 30.
3
Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.新型血小板聚集功能检测指导下的稳定型冠状动脉疾病行经皮冠状动脉介入治疗患者的个体化抗血小板治疗：一项随机对照临床试验。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):211-221. doi: 10.1093/ehjcvp/pvz059.
4
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.在不受限制的经皮冠状动脉介入治疗人群中使用双联抗血小板治疗评分预测缺血和出血事件。
Circ Cardiovasc Interv. 2018 Oct;11(10):e006853. doi: 10.1161/CIRCINTERVENTIONS.118.006853.
5
How Can We Prevent Both Bleeding and Ischemic Events After Percutaneous Coronary Intervention in High-Bleeding Risk Patients?我们如何预防高出血风险患者经皮冠状动脉介入治疗后的出血和缺血事件？
Circ J. 2022 Aug 25;86(9):1362-1364. doi: 10.1253/circj.CJ-22-0277. Epub 2022 May 25.
6
Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.PRECISE-DAPT 评分预测行经皮冠状动脉介入治疗的急性冠状动脉综合征患者出血事件的临床价值：来自 SMART-DATE 随机试验的分析。
Circ Cardiovasc Interv. 2020 May;13(5):e008530. doi: 10.1161/CIRCINTERVENTIONS.119.008530. Epub 2020 May 1.
7
[Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention].经皮冠状动脉介入治疗后出血患者的抗栓治疗管理
G Ital Cardiol (Rome). 2020 Feb;21(2 Suppl 1):34S-41S. doi: 10.1714/3311.32819.
8
Editorial: Bleeding risk factors are also ischemic-event risk factors after percutaneous coronary intervention.社论：出血风险因素也是经皮冠状动脉介入治疗后的缺血事件风险因素。
Cardiovasc Revasc Med. 2024 Feb;59:46-47. doi: 10.1016/j.carrev.2023.12.002. Epub 2023 Dec 2.
9
Geographical Variations in the Effectiveness and Safety of Abbreviated or Standard Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients at High Bleeding Risk.高出血风险患者经皮冠状动脉介入治疗后简化或标准抗血小板治疗有效性和安全性的地域差异
Can J Cardiol. 2024 Sep;40(9):1671-1674. doi: 10.1016/j.cjca.2024.01.032. Epub 2024 Feb 2.
10
In-hospital bleeding events in acute coronary syndrome patients undergoing percutaneous coronary intervention in the era of novel P2Y12 inhibitors: insights from the GReek AntiPlatelet rEgistry-GRAPE.新型P2Y12抑制剂时代接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者的院内出血事件：来自希腊抗血小板注册研究-GRAPE的见解
Int J Cardiol. 2014 Jun 1;174(1):160-2. doi: 10.1016/j.ijcard.2014.03.161. Epub 2014 Mar 28.

引用本文的文献

1
P2Y Inhibitor Monotherapy after Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后的P2Y抑制剂单药治疗
J Cardiovasc Dev Dis. 2022 Oct 6;9(10):340. doi: 10.3390/jcdd9100340.